Related Experiment Video
Updated: Aug 21, 2026

Quantitative Imaging of Lineage-specific Toll-like Receptor-mediated Signaling in Monocytes and Dendritic Cells from Small Samples of Human Blood
Published on: April 16, 2012
CD4 CTLs in supercentenarians: Signs of adaptive expansion in healthy aging
Kosuke Hashimoto1, Miki Kojima-Ishiyama2, Hajime Inokuchi3
1Institute for Protein Research, The University of Osaka, Osaka 565-0871, Japan; RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Abstract:
Our previous study identified CD4 cytotoxic T lymphocytes (CD4 CTLs) as a hallmark of supercentenarians. CD4 CTLs have primarily been studied in disease contexts; however, their role in healthy aging remains unclear. Using single-cell immune profiling, we analyzed T cells from supercentenarians and found that CD4 CTLs begin to expand around the age of 100, characterized by sequential CD27/CD28 loss without exhaustion. CD4 CTLs were dominated by large clones, with top clones averaging 33.3%, indicating repeated stimulation by persistent antigens. Furthermore, CDR3β sequences of the top clones matched those of T cells expanded in tumors, particularly lung cancer. Ex vivo stimulation experiments revealed that CD4 CTLs consist of subgroups defined by interleukin expression patterns, suggesting their plasticity within the same clone. These findings suggest that CD4 CTLs expand and diversify as an adaptation to persistent antigens, potentially contributing to longevity through cancer suppression.
Related Concept Videos
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Renewal of Intestinal Stem Cells
The Effect of Aging on Tissues
Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Cells of the Adaptive Immune Response

